Drug Profile
Research programme: anthrax vaccine - Celldex Therapeutics Inc
Alternative Names: CDX-2301Latest Information Update: 14 Apr 2011
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Class Anthrax vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 22 Feb 2007 Preclinical trials in Anthrax in USA (IM)
- 22 Feb 2007 Preclinical trials in Anthrax in USA (Intranasal)